The relation between the ghrelin receptor and FOXP3 in bladder cancer

References

• Abcam. 2020. United Kingdom: abcam PLC; 1998-2020. https://www.abcam.com/protocols/ihc-tissue-processing-protocol
   Google Scholar
• Aydin S, Ozercan I, Dagli F, Aydin S, Dogru O, Celebi S, Akin O, Guzel S. 2005. Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland. Biotech Histochem. 80:163–168. doi:10.1080/10520290500387847.
   PubMed Web of Science ®Google Scholar
• Baatar D, Patel K, Taub DD. 2011. The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol. 340:44–58. doi:10.1016/j.mce.2011.04.019.
   PubMed Web of Science ®Google Scholar
• Bagheri N, Shirzad H, Elahi S, Azadegan-Dehkordi F, Rahimian G, Shafigh M, Rashidii R, Sarafnejad A, Rafieian-Kopaei M, Faridani R. 2017. Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection. Microb Path. 110:165–175. doi:10.1016/j.micpath.2017.06.040.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 24:5373–5380. doi:10.1200/JCO.2006.05.9584.
   PubMed Web of Science ®Google Scholar
• Belloni AS, Macchi C, Rebuffat P, Conconi MT, Malendowicz LK, Parnigotto PP, Nussdorfer GG. 2004. Effect of ghrelin on the apoptotic deletion rate of different types of cells cultured in vitro. Int J Mol Med. 14:165–167.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH 17 and regulatory T cells. Nature. 441:235–238. doi:10.1038/nature04753.
   PubMed Web of Science ®Google Scholar
• Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L. 2017. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol. 72:354–365. doi:10.1016/j.eururo.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A. 2019. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 8:1570778–1570799. doi:10.1080/2162402X.2019.1570778.
   PubMed Web of Science ®Google Scholar
• Gandomani HS, Tarazoj AA, Siri FH, Karimi Rozveh A, Hosseini S, Borujeni NN, Mohammadian-Hafshejani A, Salehiniya H. 2017. Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors. Biomed Res Ther. 4:1638–1655. doi:10.15419/bmrat.v4i9.371.
   Web of Science ®Google Scholar
• Gun SY, Lee SWL, Sieow JL, Wong SC. 2019. Targeting immune cells for cancer therapy. Redox Biol. 25:101174–101190. doi:10.1016/j.redox.2019.101174.
   PubMed Web of Science ®Google Scholar
• Hattori N. 2009. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res. 19:187–197. doi:10.1016/j.ghir.2008.12.001.
   PubMed Web of Science ®Google Scholar
• Heshmati M, Soltani A, Sanaei M-J, Nahid-Samiei M, Shirzad H, Jami M-S GM. 2019. Ghrelin induces autophagy and CXCR4 expression via the SIRT1/AMPK axis in lymphoblastic leukemia cell lines. Cell Sign. 66:109492–109503. doi:10.1016/j.cellsig.2019.109492.
   PubMed Web of Science ®Google Scholar
• Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE. 2006. Levels of circulating regulatory CD4+ CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat. 98:17–29. doi:10.1007/s10549-005-9108-5.
   PubMed Web of Science ®Google Scholar
• Jemal A, Miller KD, Ma J, Siegel RL, Fedewa SA, Islami F, Devesa SS, Thun MJ. 2018. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 378:1999–2009. doi:10.1056/NEJMoa1715907.
   PubMed Web of Science ®Google Scholar
• Jóźwicki W, Brożyna AA, Siekiera J, Slominski AT. 2016. Frequency of CD4+ CD25+ Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget. 7:11450–11462. doi:10.18632/oncotarget.7199.
   PubMedGoogle Scholar
• Kraus D, Reckenbeil J, Wenghoefer M, Stark H, Frentzen M, Allam J-P, Novak N, Frede S, Götz W, Probstmeier R. 2016. Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression. Cell Mol Life Sci. 73:1287–1299. doi:10.1007/s00018-015-2048-2.
   PubMed Web of Science ®Google Scholar
• Lien G-S, Lin C-H, Yang Y-L, Wu M-S, Chen B-C. 2016. Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways. Eur J Pharmacol. 776:124–131. doi:10.1016/j.ejphar.2016.02.044.
   PubMed Web of Science ®Google Scholar
• Lin T-C HM. 2017. Ghrelin and cancer progression. Biochim Biophys Acta. 1868:51–57.
   Web of Science ®Google Scholar
• Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC. 2006. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 29:416–424. doi:10.1097/01.cji.0000205644.43735.4e.
   PubMed Web of Science ®Google Scholar
• Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. 2011. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 10:744–755. doi:10.1016/j.autrev.2011.05.004.
   PubMed Web of Science ®Google Scholar
• Nakhlé J, Pierron V, Bauchet A-L, Plas P, Thiongane A, Meyer-Losic F, Schmidlin F. 2016. Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Oncoimmunology. 5:e1145333–1145348. doi:10.1080/2162402X.2016.1145333.
   PubMed Web of Science ®Google Scholar
• Papotti M, Duregon E, Volante M. 2013. Ghrelin and tumors. The ghrelin system. Switzerland: Karger Publishers; p. 122–134.
   Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R. 2017. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 171:540–556. doi:10.1016/j.cell.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. 2013. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2:e238491–e238498.
   Web of Science ®Google Scholar
• Seim I, Crisp G, Shah ET, Jeffery PL, Chopin LK. 2017. Abundant ghrelin gene expression by monocytes: putative implications for fat accumulation and obesity. Obes Med. 5:1–3. doi:10.1016/j.obmed.2016.12.001.
   Google Scholar
• Semenza GL, Ruvolo PP. 2016. Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance. Biochim Biophys Acta Mol Cell Res. 1863:379–381. doi:10.1016/j.bbamcr.2015.12.015.
   Web of Science ®Google Scholar
• Souza-Moreira L, Delgado-Maroto V, Morell M, O’Valle F, Del Moral RG, Gonzalez-Rey E. 2013. Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells. Brain Behav Immun. 30:54–60. doi:10.1016/j.bbi.2013.01.080.
   PubMed Web of Science ®Google Scholar
• Stengel A, Taché Y. 2012. Ghrelin–a pleiotropic hormone secreted from endocrine X/A-like cells of the stomach. Front Neurosci. 6:1–16. doi:10.3389/fnins.2012.00024.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y. 2013. Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 110:17945–17950. doi:10.1073/pnas.1316796110.
   PubMed Web of Science ®Google Scholar
• Vu JP, Wang HS, Germano PM, Pisegna JR. 2011. Ghrelin in neuroendocrine tumors. Peptides. 32:2340–2347. doi:10.1016/j.peptides.2011.10.006.
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 9:606–612.
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. 2001. Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766–4772.
   PubMed Web of Science ®Google Scholar
• Yanagi S, Sato T, Kangawa K, Nakazato M. 2018. The homeostatic force of ghrelin. Cell Metab. 27:786–804. doi:10.1016/j.cmet.2018.02.008.
   PubMed Web of Science ®Google Scholar
• Zeng X, Chen S, Lin Y, Ke Z. 2018. Acylated and unacylated ghrelin inhibit apoptosis in myoblasts cocultured with colon carcinoma cells. Oncol Rep. 39:1387–1395. doi:10.3892/or.2018.6213.
   PubMed Web of Science ®Google Scholar
• Zhu J, Yao J, Huang R, Wang Y, Jia M, Huang Y. 2018. Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through PI3K/Akt/mTOR/P70S6K and ERK signaling pathways. Biochem Biophys Res Commun. 498:616–620. doi:10.1016/j.bbrc.2018.03.031.
   PubMed Web of Science ®Google Scholar